{
  "subset": "contraindication",
  "disease": "Severe hypertriglyceridaemia",
  "relation": "contraindication",
  "gold_drugs": [
    "evinacumab"
  ],
  "seeds_initial": [
    "Alprazolam",
    "Amlodipine",
    "Atorvastatin",
    "Baclofen",
    "Beta-blockers",
    "Bupropion",
    "Corticosteroids",
    "Cyclosporine",
    "Diltiazem",
    "Ethanol",
    "Fenofibrate",
    "Gemfibrozil",
    "Glyburide",
    "Immunosuppressants",
    "Isotretinoin",
    "Lipid-lowering agents",
    "Lovastatin",
    "Methylprednisolone",
    "Nandrolone",
    "Niacin",
    "Oral contraceptives",
    "Oxycodone",
    "Phentermine",
    "Prednisone",
    "Progestins",
    "Rosuvastatin",
    "Sirolimus",
    "Synthroid",
    "Thiazide diuretics",
    "Trazodone",
    "Tricor",
    "Valproic acid",
    "Verapamil",
    "Vitamin E",
    "Warfarin",
    "Zolpidem",
    "Clonidine",
    "Estrogens",
    "Hydrocodone",
    "Dexamethasone",
    "Nateglinide",
    "Quetiapine",
    "Reboxetine",
    "Sitagliptin",
    "Liraglutide",
    "Fibrates",
    "Clopidogrel",
    "Lansoprazole",
    "Olmesartan",
    "Tobacco",
    "Sodium-glucose cotransporter-2 inhibitors",
    "HIV protease inhibitors"
  ],
  "seed_history": [
    [
      "Alprazolam",
      "Amlodipine",
      "Atorvastatin",
      "Baclofen",
      "Beta-blockers",
      "Bupropion",
      "Corticosteroids",
      "Cyclosporine",
      "Diltiazem",
      "Ethanol",
      "Fenofibrate",
      "Gemfibrozil",
      "Glyburide",
      "Immunosuppressants",
      "Isotretinoin",
      "Lipid-lowering agents",
      "Lovastatin",
      "Methylprednisolone",
      "Nandrolone",
      "Niacin",
      "Oral contraceptives",
      "Oxycodone",
      "Phentermine",
      "Prednisone",
      "Progestins",
      "Rosuvastatin",
      "Sirolimus",
      "Synthroid",
      "Thiazide diuretics",
      "Trazodone",
      "Tricor",
      "Valproic acid",
      "Verapamil",
      "Vitamin E",
      "Warfarin",
      "Zolpidem",
      "Clonidine",
      "Estrogens",
      "Hydrocodone",
      "Dexamethasone",
      "Nateglinide",
      "Quetiapine",
      "Reboxetine",
      "Sitagliptin",
      "Liraglutide",
      "Fibrates",
      "Clopidogrel",
      "Lansoprazole",
      "Olmesartan",
      "Tobacco",
      "Sodium-glucose cotransporter-2 inhibitors",
      "HIV protease inhibitors"
    ],
    [
      "Fibrates",
      "Niacin",
      "Omega-3 fatty acids",
      "Statins",
      "Ezetimibe",
      "Cetilistat",
      "Orlistat",
      "Bempedoic acid",
      "PCSK9 inhibitors",
      "Insulin",
      "SGLT2 inhibitors",
      "Metformin",
      "Dapagliflozin",
      "Canagliflozin",
      "Glyburide",
      "Acarbose",
      "Rosuvastatin",
      "Atorvastatin",
      "Lovastatin",
      "Simvastatin",
      "Colesevelam",
      "Cholestyramine",
      "Lomitapide",
      "Mipomersen",
      "Dronedarone",
      "Domperidone",
      "Clonidine",
      "Amphetamines",
      "Thiazide diuretics",
      "Beta-blockers",
      "Corticosteroids",
      "Antiretroviral therapy",
      "Valproic acid",
      "Hormonal contraceptives",
      "Progestins",
      "Estrogens",
      "Anabolic steroids",
      "Tacrolimus",
      "Cyclosporine",
      "Antipsychotics",
      "Benzodiazepines",
      "Tricyclic antidepressants",
      "Lithium",
      "Carbamazepine",
      "Gabapentin",
      "Pregabalin",
      "Beta-agonists",
      "Brimonidine",
      "Dronabinol",
      "Regadenoson",
      "Ergotamine",
      "Methysergide",
      "Terbinafine",
      "Disulfiram",
      "Chlorpromazine",
      "Methadone",
      "Gabapentin enacarbil",
      "Tilidine",
      "Oxcarbazepine",
      "Quetiapine"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_fibrates",
          "name": "Fibrates"
        },
        "score": 0.68,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "存在潜在的高甘油三酯调节反馈机制",
          "对安全性反应的考虑"
        ],
        "caveats": [
          "需进一步验证安全性与效果的平衡"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_niacin",
          "name": "Niacin"
        },
        "score": 0.65,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "与高甘油三酯水平的关联性已被认可",
          "考虑与其他药物的相互作用风险"
        ],
        "caveats": [
          "安全性数据尚不充分"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_omega_3_fatty_acids",
          "name": "Omega-3 fatty acids"
        },
        "score": 0.66,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "存在调节甘油三酯的能力"
        ],
        "caveats": [
          "潜在禁忌需进一步确认"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_statins",
          "name": "Statins"
        },
        "score": 0.69,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "常用于高甘油三酯的系统性管理"
        ],
        "caveats": [
          "需确认安全性相关的长期效应"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_ezetimibe",
          "name": "Ezetimibe"
        },
        "score": 0.64,
        "graph_snapshot_ref": "GE_H5_round4",
        "key_assumptions": [
          "影响胆固醇和甘油三酯的平衡"
        ],
        "caveats": [
          "相关机制仍待深入探讨"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "相关药物均有理论支持，但潜在风险需重视",
          "reason": "多个药物在高甘油三酯管理中有支持，但同时存在与禁忌相关的安全性担忧"
        }
      ],
      "remaining_gaps": [
        "对每种药物的安全性数据仍显不足，尤其是与高甘油三酯相关的副作用"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "初始种子帮助界定了高甘油三酯的潜在处方选择"
        },
        {
          "round": 4,
          "seeds": [],
          "impact_summary": "当前候选仍需进一步探索安全性与效果的平衡"
        }
      ],
      "lessons": [
        "加强对药物安全性的重视，尤其是禁忌与副作用之间的权衡",
        "在临床实施的背景下更好地界定每种药物的适应症"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "继续评估药物的安全性与现实效果的平衡，必要时修订推荐"
      },
      {
        "role": "Skeptic",
        "patch": "加强对禁忌与副作用的实验数据收集与分析"
      }
    ],
    "heuristics": [
      {
        "when": "高甘油三酯相关治疗",
        "then": "解除对药物潜在副作用的关注，寻找多样化的治疗方案"
      },
      {
        "when": "安全性问题",
        "then": "邀请更多临床数据以确认药物的实际效果与风险"
      }
    ]
  }
}